Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2011-05-03
2011-05-03
Mosher, Mary E (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S287200, C530S350000
Reexamination Certificate
active
07935490
ABSTRACT:
The present invention relates to a solid phase immunoassay comprising on said solid phase an antigen in the presence of a reducing agent. The present invention also relates to a method for purifying a cysteine containing recombinantly expressed protein comprising at least 2, preferably 3 or 4 and even more preferably all of the following steps: (a) sulphonation of a lysate from recombinant host cells or lysis of recombinant host cells in the presence of guanidinium chloride followed by a subsequent sulphonation of the cell lysate, (b) treatment with a zwitterionic detergent, preferably after removal of the cell debris, (c) purification of the sulphonated version of the recombinant protein or purification of the sulphonated version of the recombinant protein with subsequent removal of the zwitterionic detergent, with said purification being preferably chromatography, more preferably a Ni-IMAC chromatography with said recombinant protein being a His-tagged recombinant protein, (d) desulphonation of the sulphonated version of the recombinant protein, preferably with a molar excess of DTT, (e) storage in the presence of a molar excess of DTT. The present invention also relates to novel HCV NS3 sequences as depicted in FIGS.1-8.
REFERENCES:
patent: 4616078 (1986-10-01), Dimarchi
patent: 5585258 (1996-12-01), Houghton et al.
patent: 5616460 (1997-04-01), Figard
patent: 5681695 (1997-10-01), Decker et al.
patent: 5705330 (1998-01-01), Shah et al.
patent: 6036579 (2000-03-01), Cook et al.
patent: 6096319 (2000-08-01), Seidel et al.
patent: 6270960 (2001-08-01), Seidel et al.
patent: 6306579 (2001-10-01), Seidel et al.
patent: 0 139 526 (1985-05-01), None
patent: 0 346 500 (1989-12-01), None
patent: 0 361 830 (1990-04-01), None
patent: 06 074 956 (1994-03-01), None
patent: 06074956 (1994-03-01), None
patent: 91/15575 (1991-10-01), None
patent: WO 93/00365 (1993-01-01), None
patent: WO 94/25601 (1994-11-01), None
patent: WO 9512677 (1995-05-01), None
patent: WO 9512677 (1995-05-01), None
patent: WO 95/30686 (1995-11-01), None
patent: 96/06355 (1996-02-01), None
patent: WO 96/00365 (1996-02-01), None
patent: WO 96 04385 (1996-02-01), None
patent: WO 96/13590 (1996-05-01), None
patent: WO 96/32004 (1996-10-01), None
patent: WO 96/41164 (1996-12-01), None
patent: WO 97/12043 (1997-04-01), None
patent: WO 97 12043 (1997-04-01), None
patent: WO 97/44469 (1997-11-01), None
Icardi et al, J. Clinical Microbiology 1997, vol. 35, pp. 2331-2336.
Harlow et al, Antibodies: A Laboratory Manual, N.Y., Cold Spring Harbor, 1988, pp. 606-607; QR186.7.A53.
JP 60-126300 (corresponding to EP 0 139 526).
JP 9-503396(corresponding to EP WO 96/04385).
JP 9-504534 (corresponding to WO 95/12677).
JP 5-507612 (corresponding to WO 91/15575).
Masuda et al, “Efficient production of the C-terminal domain of secretory leukoprotease inhibitor as a thrombin-cleavable fusion protein inEscherichia coli”, 1996, Protein Engineering 9, No. 101-106.
Dibella et al, “Expression and Folding of Recombinant Bovine Prethrombin-2 and Its Activation to Thrombin”, 1995, Journal of Biological Chemistry, vol. 270, No. 1, 163-169.
Fischer et al. 1993, “Isolation, Renaturation, and Formation of Disulfide Bonds of Eukaryotic Proteins Expressed inEscherichia colias Inclusion Bodies”, Biotechnology & Bioengineering 41, No. 1, 3-13.
Cypress Diagnostics—HIV1/2 Quick Test, 1996-2002, pp. 1-5.
Cypress Diagnostics—Anti-HCV Rapid Test, 1996-2002, pp. 1-2.
Van Doorn et al, “Hepatitis C Virus Antibody Detection by a Line ImmunoAssay and (Near) Full Length Genomic RNA Detection by a New RNA-Capture Polymerase Chain Reaction”, 1992—Journal of Medical Virology, 38:298-304.
Calbiochem—Empigen BB fact sheet, Cat. No. 324690, revised Jan. 4, 1999.
Lin et al, “The hepatitis C virus NS3 serine proteinase and NS4A cofactor: Establishment of a cell-free trans-processing assay”, 1995, Proc Natl Acad Sci USA, vol. 92, 7622-7626.
Lin et al, “Hepatitis C Virus NS3 Serine Proteinase:trans-Cleavage Requirements and Processing Kinetics”, 1994, Journal of Virology, vol. 68, No. 12, 8147-8157.
Thomson and Liang 2000 -Molecular Biology of Hepatitis C virus, p. 1 and p. 12; In: Hepatitis C (Liang, Hoofnagle, eds), Academic Press.
Majzoub et al, “Vasopressin and Oxytocin mRNA Regulation in the Rat Assessed by Hybridization with Synthetic Oligonucleotides”, 1983, The Journal of Biological Chemistry, vol. 258,No. 23, 14061-14064.
File history of U.S. Appl. No. 09/686,964, retrieved from the PTO IFW on Sep. 26, 2007.
Chan et al, “Construction and selection of recombinant plasmids containing full-length complementary DNAs corresponding to rat insulins I and II”, 1979, Proc Natl Acad Sci USA, vol. 76, No. 10, 5036-5040.
Bosman Alfons
Louwagie Joost
Maertens Geert
Sablon Erwin
Zrein Maan
Hill Myron G
Mosher Mary E
N.V. Innogenetics
Nixon & Vanderhye P.C.
LandOfFree
Immunodiagnostic assays using reducing agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunodiagnostic assays using reducing agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunodiagnostic assays using reducing agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2663397